Compare Incyte Corporation (INCY) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs S&P500 ETF — how do they compare? Incyte Corporation trades at $113.79 (market cap $22.85B), while S&P500 ETF trades at $778.19 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 36× Incyte Corporation's market cap, and S&P500 ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and S&P500 ETF for 205 Days on average.
| INCY | SPY | |
|---|---|---|
Market Cap | $22.85B | $821.54B |
Volume | 1,927,029 | 40,070,358 |
Sector | Health | — |
52-Week High | $129.93 | $779.14 |
52-Week Low | $83.80 | $631.99 |
Typical Hold Time | 33 Days | 205 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SPY (SPDR S&P 500 ETF Trust) trades at $778.18, up 0.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.54 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates and profit growth expectations of 35% for 2026. Technical support sits at $771 with resistance at $777.
Outlook remains cautiously optimistic given the ETF's broad market exposure, though risks include potential profit growth deceleration to 15% in 2027 and market-wide valuation concerns. The dividend yield of approximately 0.24% provides modest income, while institutional positioning favors large-cap stability amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
